Author's response to reviews

Title: Radiological and pathological findings of a metastatic composite paraganglioma with neuroblastoma - a case report

Authors:

Florian R Fritzsche (florian.fritzsche@usz.ch)
Peter K Bode (peterkarl.bode@usz.ch)
Sonja Koch (sonja.koch@ksw.ch)
Thomas Frauenfelder (thomas.frauenfelder@usz.ch)

Version: 3 Date: 15 June 2010

Author's response to reviews: see over
Dear Sirs,

Thank you for reviewing our manuscript “Radiological and pathological findings of a metastatic composite paraganglioma with neuroblastoma – a case report”. We found the reviewers’ comments very helpful to improve the manuscript. Please find the answers to the reviewers comments itemized point by point.

**Reviewer 1**

1. *It's a good case report especially in the iconographic section.*
Reviewer 2

This case is rare case of composite paraganglioma-neuroblastoma. However, this report includes several problems.
1. Ultrasonography and CT findings of metastatic hepatic tumor should be described.

Answer: The requested imaging findings have been included in the case description.

2. Which tumor did metastasize to the liver? Paraganglioma or neuroblastoma? Malignant paraganglioma can make metastasis. Did authors treated with this patient with palliative chemo-and radioptherapy without histological confirmation of liver metastasis?

Answer: We agree with the reviewer that these are important points to be addressed. Of course metastasis was histologically confirmed (lymph nodes and skin) prior to treatment. The analysed metastases were from the neuroblastoma compartment of the tumour. This information was included in the case description.

3. Treatment should be described in detail. In palliative chemo-and radioptherapy, what kind of anticancer drugs did authors use? What was the amount of anticancer drugs authors used? And radiation volume?

Answer: The palliative therapy started with three cycles of Paraplatin and Etopophos. With tumour progression a palliative radiotherapy with 10x3 Gy at multiple locations followed. Subsequently, a chemotherapy with CHOP was started and finally (after about two months) changed to taxotere/prednisone. This information was included in the case description.
Reviewer 1 & 2

Needs some language corrections before being published.

Answer: The whole manuscript has been thoroughly copyedited by a native speaker (Victoria Salter/ Oxford).

We hope that the improvements made to the manuscript render this work acceptable for publication in the Journal of Medical Case Reports. Please do not hesitate to contact us for any further questions.

Best regards

Florian Fritzsche            Thomas Frauenfelder